Program
SAL0120
A development code. Also written as “SAL0120 1mg”, “SAL0120 2mg” and “SAL0120 4mg”.
Its studies are mostly in Hypertension · Renal Insufficiency, Chronic, led by Shenzhen Salubris Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 21 open or running | phase 3since Aug 24, 2026 | Jul 16, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2026First study: phase 2 study in Renal Insufficiency, ChronicFirst studyNCT07716618 · 320 enrolled · China
- Aug 24, 2026Phase 3 study in Uncontrolled HypertensionPhase 3 reachedNCT07790120 · 256 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07790120Uncontrolled Hypertension · China | 3 | Completed | Jul 2, 2026 | 256 |
| NCT07716618Renal Insufficiency, Chronic · China | 2 | Active, not recruiting | May 27, 2026 | 320 |
How it is read
Names in the registry
- “SAL0120”, 1 entry
- “SAL0120 1mg”, 1 entry
- “SAL0120 2mg”, 1 entry
- “SAL0120 4mg”, 1 entry
Codes read as this program: SAL0120.
Conditions, from the studies’ own filings
- Hypertension, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.